Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 544

1.

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease.

Ballard C, Atri A, Boneva N, Cummings JL, Frölich L, Molinuevo JL, Tariot PN, Raket LL.

Alzheimers Dement (N Y). 2019 May 20;5:164-174. doi: 10.1016/j.trci.2019.04.001. eCollection 2019.

2.

Emotional and physical reactions to perceived discrimination, language preference, and health-related quality of life among Latinos and Whites.

White K, Lawrence JA, Cummings JL, Fisk C.

Qual Life Res. 2019 Jun 10. doi: 10.1007/s11136-019-02222-9. [Epub ahead of print]

PMID:
31183603
3.

Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer's Disease.

Bayram E, Shan G, Cummings JL.

J Alzheimers Dis. 2019;69(4):953-961. doi: 10.3233/JAD-181285.

PMID:
31127776
4.

Socially Assigned Race and Diabetes: Findings from the Arizona Behavioral Risk Factor Surveillance System, 2013-2014.

Lawrence JA, White K, Cummings JL, Hardin JW, Torres ME.

J Racial Ethn Health Disparities. 2019 May 7. doi: 10.1007/s40615-019-00593-w. [Epub ahead of print]

PMID:
31065999
5.

Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.

Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D.

N Engl J Med. 2019 Apr 11;380(15):1408-1420. doi: 10.1056/NEJMoa1812840.

PMID:
30970186
6.

Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options.

Cummings JL, Tong G, Ballard C.

J Alzheimers Dis. 2019;67(3):779-794. doi: 10.3233/JAD-180766.

7.

Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease.

Frölich L, Atri A, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Geist MA, Raket LL, Cummings JL.

J Alzheimers Dis. 2019;67(1):303-313. doi: 10.3233/JAD-180595.

PMID:
30636738
8.

Unsuccessful trials of therapies for Alzheimer's disease.

Schott JM, Aisen PS, Cummings JL, Howard RJ, Fox NC.

Lancet. 2019 Jan 5;393(10166):29. doi: 10.1016/S0140-6736(18)31896-8. No abstract available.

PMID:
30614456
9.

Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program.

Cummings JL, Atri A, Ballard C, Boneva N, Frölich L, Molinuevo JL, Raket LL, Tariot PN.

Alzheimers Res Ther. 2018 Nov 24;10(1):116. doi: 10.1186/s13195-018-0443-2.

10.

Default Mode Network Lateralization and Memory in Healthy Aging and Alzheimer's Disease.

Banks SJ, Zhuang X, Bayram E, Bird C, Cordes D, Caldwell JZK, Cummings JL; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;66(3):1223-1234. doi: 10.3233/JAD-180541.

11.

Genetic Risk of Alzheimer's Disease: Three Wishes Now That the Genie is Out of the Bottle.

Frank L, Wesson Ashford J, Bayley PJ, Borson S, Buschke H, Cohen D, Cummings JL, Davies P, Dean M, Finkel SI, Hyer L, Perry G, Powers RE, Schmitt F.

J Alzheimers Dis. 2018;66(2):421-423. doi: 10.3233/JAD-180629.

12.

Advances in functional magnetic resonance imaging data analysis methods using Empirical Mode Decomposition to investigate temporal changes in early Parkinson's disease.

Cordes D, Zhuang X, Kaleem M, Sreenivasan K, Yang Z, Mishra V, Banks SJ, Bluett B, Cummings JL.

Alzheimers Dement (N Y). 2018 Jun 14;4:372-386. doi: 10.1016/j.trci.2018.04.009. eCollection 2018.

13.

Statistical advances in clinical trials and clinical research.

Shan G, Banks S, Miller JB, Ritter A, Bernick C, Lombardo J, Cummings JL.

Alzheimers Dement (N Y). 2018 Jun 14;4:366-371. doi: 10.1016/j.trci.2018.04.006. eCollection 2018.

14.

Neurodegeneration research: Advances in clinical translational neuroscience infrastructure and methods.

Cummings JL, Fulkerson N.

Alzheimers Dement (N Y). 2018 Jun 1;4:326-329. doi: 10.1016/j.trci.2018.03.008. eCollection 2018. No abstract available.

15.

Dietary Cellulose Supplementation Modulates the Immune Response in a Murine Endotoxemia Model.

Di Caro V, Cummings JL, Alcamo AM, Piganelli JD, Clark RSB, Morowitz MJ, Aneja RK.

Shock. 2019 Apr;51(4):526-534. doi: 10.1097/SHK.0000000000001180.

PMID:
30080745
16.

Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study.

Torosyan N, Sethanandha C, Grill JD, Dilley ML, Lee J, Cummings JL, Ossinalde C, Silverman DH.

Exp Gerontol. 2018 Oct 1;111:118-121. doi: 10.1016/j.exger.2018.07.009. Epub 2018 Jul 10.

PMID:
30006299
17.

Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume.

Caldwell JZK, Berg JL, Shan G, Cummings JL, Banks SJ; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;64(1):79-89. doi: 10.3233/JAD-180028.

18.

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D.

N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441.

19.

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.

Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R.

Neurology. 2018 May 22;90(21):e1889-e1897. doi: 10.1212/WNL.0000000000005550. Epub 2018 Apr 25.

20.

Comparing the Electronic and Standard Versions of the Montreal Cognitive Assessment in an Outpatient Memory Disorders Clinic: A Validation Study.

Berg JL, Durant J, Léger GC, Cummings JL, Nasreddine Z, Miller JB.

J Alzheimers Dis. 2018;62(1):93-97. doi: 10.3233/JAD-170896.

Supplemental Content

Loading ...
Support Center